CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 × 106 cells/l

AIDS

Volumn 19, Issue 3, 2005, Pages 287-294

  Mussini, Cristina ^a   Bedini, Andrea ^a   Borghi, Vanni ^a   Guaraldi, Giovanni ^a   Esposito, Roberto ^a   Barchi, Enrico ^b   Cozzi Lepri, Alessandro ^c   Phillips, Andrew N ^c   Ortolani, Patrizia ^b   Bratt, Göran ^d   Eriksson, Lars E ^d   Sighinolfi, Laura ^e   Cossarizza, Andrea ^f   D'Arminio Monforte, Antonella ^g   De Luca, Andrea ^h   Di Giambenedetto, Simona ^h   Antinori, Andrea ⁱ  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Department of Infectious Diseases ^*  (Italy)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

^e UNIVERSITY OF FERRARA   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

CD4 cell count; Cholesterol; Treatment interruption; Triglycerides; Viral load; Viral rebound

Indexed keywords

ATAZANAVIR; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MONITORING; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REBOUND; RISK ASSESSMENT; T LYMPHOCYTE; VIRUS LOAD;

EID: 15444362420     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Dybul M, Nies-Kraske E, Daucher M, Hallahan C, Csako G, Yoder C, et al. A randomized, controlled trial of long cycle structured intermittent versus continuous ARV therapy for chronic HIV infection. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 681b].
2. Ananworanich J, Nuesch R, Le-Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S, et al. Failures of 1 week on 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17:F33-F37.
3. Vella S, Giuliano N, Palmisano L, Bucciardini R, Andreotti M, Arcieri R, et al. ISS-PART: a prospective, randomized, multicentre clinical trial of intermittent therapy in HIV+ subjects with persistent suppression of viral replication. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 66].
4. Tarwater PM, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis 2003; 37:1541-1548.
5. Ruiz L, Gomez L, Domingo P, Romeu J, Tambussi C, Martinez-Picado J, et al. A multicenter, randomized controlled trial of continuous versus intermittent HAART guided by CD4+ T-cell counts and plasma HIV-1 RNA levels. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 65].
6. Ananworanich J, Cardiello P, Srasuebkul P, Samor T, Hassink E, Mahanontharit A, et al. HIV-NAT 001.4: a prospective randomized trial of structured treatment interruption in patients with chronic HIV infection. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 64].
7. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 2004; 18:439-446.
8. 6cells/l. AIDS 2002; 16:1551-1554.
9. Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, Joos B, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188:1433-1443.
10. Palmisano L, Giuliano M, Bucciardini R, Galluzzo CM, Andreotti M, Fragola V, et al. Emergence of resistance mutations during intermittent HAART. Rate, predicting factors and effect on virological response. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 552].
11. Phillips AN, Youle MS, Lampe F, Johnson M, Sabin CA, Lepri AC, Loveday C. Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection. AIDS 2003; 17:1009-1016.
12. d'Arminio Monforte A, Cozzi-Lepri A, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. ICONA Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14:499-507.
13. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Cozzi-Lepri A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15:185-194.
14. Boyer PL, Hughes SH. Analysis of mutation at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1995; 39:1624-1628.
15. Laird NM, Ware JH. Random effects models for longitudinal data. Biometrics 1982; 38:963-974.
16. Hogg RS, Havlir D, Miller V, Montaner JSG. To stop or not to stop: that is the question but what is the answer? AIDS 2002; 16:787-789.
17. Deeks SG, Hirschel B. Supervised interruptions of antiretroviral therapy. AIDS 2002; 16 (suppl. 4):2981-2987.
18. Trotta MP, Ammassari A, Cozzi-Lepri A, Zaccarelli M, Castelli F, Narciso P, et al. for the Adherence Italian Cohort Naive Antiretrovirals (AdlCONA) and Adherence Spallanzani (AdeSpall) Study Groups. Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. AIDS 2003; 17:1099-1102.
19. Poulton MB, Sabin CA, Fisher M. Immunological changes during treatment interruptions: risk factors and clinical sequelae. AIDS 2003; 17:126-128.
20. Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003; 4:1-41.
21. Yeni PC, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288:222-235.
22. Touloumi G, Pocock SJ, Babiker AC, Darbyshire JH. Impact of missing data due to selective dropouts in cohort studies and clinical trials. Epidemiology 2002; 13:347-355.
23. Tubiana R, Ghosn J, De-Sa M, Wirden M, Gautheret-Dejean A, Bricaire F, et al. Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission. AIDS 2002; 16:1083.
24. Ananworanich J, Phanuphak N, Nuesch R, Apateerapong W, Rojnuckarin P, Ubolyam S, et al. Recurring thrombocytopenia associated with structured treatment interruption in patients with human immunodeficiency virus infection. Clin Infect Dis 2003; 37:723-725.
25. Worthington MG, Ross JJ. Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy: implications for structured treatment interruptions. AIDS 2003; 17:2145-2146.
26. Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2002; 163:1220-1226.
27. Taylor S, Allen S, Fidler S, White D, Gibbons S, Fox J, et al. Stop Study: after discontinuation of efavirenz, plasma concentrations may persist for 2 weeks or longer. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 131].